Data from an Additional Six Months of Imetelstat Treatment and Follow-Up since ASH 2012
Imetelstat Continues to be Well Tolerated with No New Safety Signals Reported; No Patients Have Discontinued Treatment Due to Drug-Related Adverse Events
Hematologic and Molecular Responses are Maintained
MENLO PARK, Calif., June 16, 2013 - Geron Corporation today announced that updated clinical results from the company`s Phase 2 trial of imetelstat in essential thrombocytopenia (ET) were presented in an oral session at the 18th Congress of the European Hematology Association (EHA) in Stockholm by a principal investigator of the trial, Prof. Dr. med. Gabriela M. Baerlocher, of the University Hospital and University of Bern, Switzerland. ET is a chronic blood disorder that is representative of a group of diseases known as myeloproliferative neoplasms (MPNs). The initial trial results from 14 patients with ET were presented at the American Society of Hematology (ASH) annual meeting in December 2012. The updated results, which showed robust hematologic and molecular responses in patients treated with imetelstat, included data for an additional six months of treatment and follow-up for the original 14 patients, as well as data from four additional patients enrolled in the trial after the data cut-off for the ASH presentation.
"The observed 100% hematologic response rate in the updated data set, accompanied by a molecular response rate of 88% among the patients who had a JAK2 V617F mutation, are consistent with the data reported at ASH last year," said Prof. Baerlocher. "Imetelstat continues to be well tolerated in this trial. With no patients on treatment losing hematologic response, and molecular responses maintained in 86% of the patients, the drug also appears to have good durability of its effects on the disease."
I am surprised that there has not been more recognition that Geron has a very interesting and potentially very profitable product & treatment. Pipeline is normally huge in this business, and brings the big boys around. What's the Problem?
It seems to me that there needs to be some follow-up comments about this "advance in the technology". To me (the layman) this sounds very important to Geron and its future value. Am I wrong and missing something? Is this "an important advance" for Imetelstat, and the treatment of "blood disorders? Please explain.
lws2000, did you even read the news release you posted under the title, "Good News"?
apparently not because you would have noticed that the article cites a blood disorder for which imetelstat is not even being studied/tested.
essential thrombocythemia is NOT essential thrombocytopenia.
I have no idea what either of these blood disorders are, or if they are similar (--"repesentative of a group of diseases"). This sounds very impressive for Geron & Imetelstat. Please provide some insight and background.--Thanks